Abstract: Disclosed are a preparation method of a display panel, a display panel and a displaying device. The display panel comprises a plurality of first-color subpixels, and each first-color subpixel comprises a base, the base comprising a first driving electrode and a second driving electrode; a flat layer disposed on the side, near the first driving electrode and the second driving electrode, of the base; a patterned passivation layer and at least one first electrode disposed on the side, away from the base, of the flat layer, the first electrode being connected with the first driving electrode through via holes penetrating the flat layer; and at least one second electrode disposed on the side, away from the base, of the passivation layer, the second electrode being connected with the second driving electrode through via holes penetrating the passivation layer and the flat layer.

Abstract: The present disclosure relates to an array substrate, a manufacturing method thereof, a three-dimensional display panel, and a display device. The array substrate includes a plurality of sub-pixels arranged in an array. Each sub-pixel includes a first composite region and a second composite region alternately arranged, as well as a substrate; a partition portion formed in the second composite region; a pixel electrode including a first composite electrode formed in the first composite region and a second composite electrode formed on the partition portion; an organic light emitting layer formed on a side of the pixel electrode away from the substrate; a pixel defining layer formed on the substrate provided around the organic light emitting layer; a common electrode having a polarity opposite to the pixel electrode formed on a side of organic light emitting layer away from the substrate; and a packaging layer.

Abstract: Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.

Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.

Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.

Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.

Abstract: A crucible, a vacuum evaporation device and a vacuum evaporation system are disclosed. In one embodiment, the crucible includes a crucible body for accommodating an evaporation material therein, a nozzle disposed at a mouth of the crucible body, and a holding groove formed at the outer circumference of the nozzle and configured for accommodating the evaporation material overflowed from the nozzle therein, so that, the overflowed evaporation material (especially aluminum material) is prevented from falling into an interior of a heating source, avoiding damage to a heating element due to a short circuit, and meanwhile, condition of overflow of the evaporation material will be checked easily by observing the holding groove. The crucible according to some embodiments adopts a structural design with a large bottom and small mouth, improving heating area and evaporation rate of the evaporation material.

Abstract: A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.

Abstract: A crucible, an evaporation device and an evaporation system are provided in embodiments of the disclosure, the crucible comprising a crucible body, which defines therein an accommodation chamber which is configured to accommodate a material to be heated, and the crucible further comprises a collector, which is located in the accommodation chamber and configured to collect impurities produced during an evaporation in the crucible and opens towards an upper portion of the accommodation chamber facing away from a bottom of the crucible body.

Abstract: Embodiments of the present disclosure provide an evaporation crucible and an evaporation device. The evaporation crucible includes a crucible body and a fluid guide member communicated with the crucible body, and a plurality of gas inlet nozzles being distributed on a side wall of the fluid guide member.

Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.

Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.

Abstract: A crucible, a vacuum evaporation device and a vacuum evaporation system are disclosed. In one embodiment, the crucible includes a crucible body for accommodating an evaporation material therein, a nozzle disposed at a mouth of the crucible body, and a holding groove formed at the outer circumference of the nozzle and configured for accommodating the evaporation material overflowed from the nozzle therein, so that, the overflowed evaporation material (especially aluminum material) is prevented from falling into an interior of a heating source, avoiding damage to a heating element due to a short circuit, and meanwhile, condition of overflow of the evaporation material will be checked easily by observing the holding groove. The crucible according to some embodiments adopts a structural design with a large bottom and small mouth, improving heating area and evaporation rate of the evaporation material.

Abstract: Embodiments of the present disclosure provide an evaporation crucible and an evaporation device. The evaporation crucible includes a crucible body and a fluid guide member communicated with the crucible body, and a plurality of gas inlet nozzles being distributed on a side wall of the fluid guide member.

Abstract: A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.

Abstract: Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.

Abstract: Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.

Abstract: Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.